Literature DB >> 30281314

Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Michael A Collier, Robert D Junkins, Matthew D Gallovic, Brandon M Johnson, Monica M Johnson, Andrew N Macintyre1, Gregory D Sempowski1, Eric M Bachelder, Jenny P-Y Ting, Kristy M Ainslie.   

Abstract

Vaccines are the most effective tool for preventing infectious diseases; however, subunit vaccines, considered the safest type, suffer from poor immunogenicity and require adjuvants to create a strong and sustained immune response. As adjuvants, pathogen-associated molecular patterns (PAMPs) offer potent immunostimulatory properties and defined mechanisms of action through their cognate pattern recognition receptors (PRRs). Their activity can be further enhanced through combining two or more PAMPs, particularly those that activate multiple immune signaling pathways. However, the cytosolic localization of many PRRs requires intracellular delivery of PAMPs for optimal biological activity, which is particularly true of the stimulator of interferon genes (STING) PRR. Using acetalated dextran (Ace-DEX) microparticles (MPs) encapsulating STING agonist 3'3'-cyclic GMP-AMP (cGAMP) combined with soluble PAMPS, we screened the effect of codelivery of adjuvants using primary mouse bone marrow derived dendritic cells (BMDCs). We identified that codelivery of cGAMP MPs and soluble Toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) elicited the broadest cytokine response. cGAMP and R848 were then coencapsulated within Ace-DEX MPs via electrospray. Using the model antigen ovalbumin, we observed that Ace-DEX MPs coencapsulating cGAMP and R848 (cGAMP/R848 Ace-DEX MPs) induced antigen-specific cellular immunity, and a balanced Th1/Th2 humoral response that was greater than cGAMP Ace-DEX MPs alone and PAMPs delivered in separate MPs. These data indicate that polymeric Ace-DEX MPs loaded with STING and TLR7/8 agonists represent a potent cellular and humoral vaccine adjuvant.

Entities:  

Keywords:  STING; acetalated dextran; cGAMP adjuvant; microparticles; vaccine adjuvants

Mesh:

Substances:

Year:  2018        PMID: 30281314      PMCID: PMC6261357          DOI: 10.1021/acs.molpharmaceut.8b00579

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  68 in total

1.  Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Authors:  Hiroyuki Kayamuro; Yasuo Yoshioka; Yasuhiro Abe; Shuhei Arita; Kazufumi Katayama; Tetsuya Nomura; Tomoaki Yoshikawa; Ritsuko Kubota-Koketsu; Kazuyoshi Ikuta; Shigefumi Okamoto; Yasuko Mori; Jun Kunisawa; Hiroshi Kiyono; Norio Itoh; Kazuya Nagano; Haruhiko Kamada; Yasuo Tsutsumi; Shin-ichi Tsunoda
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

2.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

Review 3.  Development of synthetic biodegradable microparticulate vaccines: a roller coaster story.

Authors:  Pål Johansen; Julia M Martínez Gómez; Bruno Gander
Journal:  Expert Rev Vaccines       Date:  2007-08       Impact factor: 5.217

Review 4.  The mechanism of action of MF59 - an innately attractive adjuvant formulation.

Authors:  D T O'Hagan; G S Ott; E De Gregorio; A Seubert
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

5.  Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.

Authors:  Tyler J Goodwin; Leaf Huang
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

6.  Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Authors:  Jurjen Tel; Annechien J A Lambeck; Luis J Cruz; Paul J Tacken; I Jolanda M de Vries; Carl G Figdor
Journal:  J Immunol       Date:  2010-03-19       Impact factor: 5.422

7.  DNA vaccination based on pyolysin co-immunized with IL-1β enhances host antibacterial immunity against Trueperella pyogenes infection.

Authors:  Ting Huang; Kelei Zhao; Ziqi Zhang; Ce Tang; Xiuyue Zhang; Bisong Yue
Journal:  Vaccine       Date:  2016-04-15       Impact factor: 3.641

Review 8.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

9.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.

Authors:  Qing Zhu; James Talton; Guofeng Zhang; Tshaka Cunningham; Zijian Wang; Robert C Waters; James Kirk; Bärbel Eppler; Dennis M Klinman; Yongjun Sui; Susan Gagnon; Igor M Belyakov; Russell J Mumper; Jay A Berzofsky
Journal:  Nat Med       Date:  2012-07-15       Impact factor: 53.440

View more
  24 in total

1.  Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.

Authors:  Daniel Shae; Jessalyn J Baljon; Mohamed Wehbe; Plamen P Christov; Kyle W Becker; Amrendra Kumar; Naveenchandra Suryadevara; Carcia S Carson; Christian R Palmer; Frances C Knight; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2020-07-31       Impact factor: 15.881

2.  A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity.

Authors:  Rebekah Watkins-Schulz; Pamela Tiet; Matthew D Gallovic; Robert D Junkins; Cole Batty; Eric M Bachelder; Kristy M Ainslie; Jenny P Y Ting
Journal:  Biomaterials       Date:  2019-03-14       Impact factor: 12.479

Review 3.  Bioinspired nucleic acid structures for immune modulation.

Authors:  Cameron Louttit; Kyung Soo Park; James J Moon
Journal:  Biomaterials       Date:  2019-06-19       Impact factor: 12.479

4.  Metal-Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine.

Authors:  Meital Eckshtain-Levi; Cole J Batty; Liubov M Lifshits; Brandon McCammitt; Kathryn M Moore; Eva A Amouzougan; Rebeca T Stiepel; Eliza Duggan; Ted M Ross; Eric M Bachelder; Kristy M Ainslie
Journal:  ACS Appl Mater Interfaces       Date:  2022-06-15       Impact factor: 10.383

Review 5.  A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.

Authors:  Ahmad M Aldossary; Chinedu S M Ekweremadu; Ifunanya M Offe; Haya A Alfassam; Sooyeon Han; Vivian C Onyali; Chukwuebuka H Ozoude; Emmanuel A Ayeni; Chinekwu S Nwagwu; Abdulrahman A Halwani; Nada H Almozain; Essam A Tawfik
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

6.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

Review 7.  Influenza Virus and SARS-CoV-2 Vaccines.

Authors:  Adam M Sandor; Michael S Sturdivant; Jenny P Y Ting
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.426

8.  A versatile photothermal vaccine based on acid-responsive glyco-nanoplatform for synergistic therapy of cancer.

Authors:  Yanan Gao; Qingyu Zhao; Min Xiao; Xuefei Huang; Xuanjun Wu
Journal:  Biomaterials       Date:  2021-04-08       Impact factor: 15.304

9.  Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.

Authors:  Dinh Chuong Nguyen; Daniel Shae; Hayden M Pagendarm; Kyle W Becker; Mohamed Wehbe; Kameron V Kilchrist; Lucinda E Pastora; Christian R Palmer; Pedro Seber; Plamen P Christov; Craig L Duvall; John T Wilson
Journal:  Adv Healthc Mater       Date:  2020-11-23       Impact factor: 9.933

Review 10.  Nanodelivery of STING agonists against cancer and infectious diseases.

Authors:  Jiarong Zhou; Christian J Ventura; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Aspects Med       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.